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ABSTRACT 
A variety of formulation strategies have been developed to mitigate the inadequate aqueous 
solubility of certain therapeutic agents. Amongst these, achieving supersaturation in vivo is a 
promising approach to improve the extent of oral absorption. Due to the thermodynamic instability 
of supersaturated solutions, inhibitors are needed to kinetically hinder crystallization. In addition 
to commonly used polymeric additives, bile salts, naturally present in the gastrointestinal tract, 
have been shown to exhibit crystallization inhibition properties. However, the impact of bile salts 
on solution thermodynamics is not well understood, although this knowledge is essential in order 
to explore the mechanism of crystallization inhibition.  To better describe solution 
thermodynamics in the presence of bile salts, a side-by-side diffusion cell was used to evaluate 
solute flux for solutions of telaprevir in the absence and presence of the six most abundant bile 
salts in human intestinal fluid at various solute concentrations; flux measurements provide 
information about the solute thermodynamic activity and hence can provide an improved 
measurement of supersaturation in complex solutions. Trihydroxy bile salts had minimal impact 
on solution phase boundaries as well as solute flux, while micellar dihydroxy bile salts solubilized 
telaprevir leading to reduced solute flux across the membrane. An inconsistency between the 
concentration-based supersaturation ratio and that based on solute thermodynamic activity (the 
fundamental driving force for crystallization) was noted, suggesting that the activity-based 
supersaturation should be determined to better interpret any modification in crystallization kinetics 
in the presence of these additives.  These findings indicate that bile salts are not interchangeable 
from a thermodynamic perspective, and provide a foundation for further studies evaluating the 
mechanism of crystallization inhibition. 
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INTRODUCTION 
 There are two key determinants to oral drug absorption: solubility and permeability. 1 
The solubility of the drug in the gastrointestinal (GI) tract and the permeability of the drug through 
the GI membrane dictate the extent of oral drug absorption, and thus affect the bioavailability of 
the drug. Over the past few decades, there has been an increase in the number of poorly soluble 
drugs in the developmental pipeline.2, 3 To tackle the issue of inadequate solubility, a wide variety 
of formulation strategies have been evaluated and applied, including salts, cosolvents, 
solubilization with lipids and surfactants, nanocrystals, and amorphous solid dispersions.3 
Recently, there has been increasing attention paid to the trade-off between solubility increase and 
apparent permeability decrease when some of these strategies are employed. Significant reduction 
in membrane mass transport was observed for systems in the presence of solubilizing additives 
due to a change in solute thermodynamic activity. 4 Miller et al.5 described the advantages of 
implementing supersaturation strategies via amorphous solid dispersion, in which increased 
apparent solubility is achievable without the expense of reduced apparent membrane permeability. 
 Guzman et al.6 SURSRVHGWKH³VSULQJDQGSDUDFKXWH´DSSURDFKWRGHVFULEHWKHFRQFHSW
of employing supersaturation as a strategy to improve oral absorption of poorly soluble drugs. A 
supersaturated drug solution can be generated with different formulation strategies (the spring). In 
the absence of rapid crystallization, the maximum achievable supersaturation of a compound is 
limited by its amorphous solubility,7 above which phase separation occurs due to the formation of 
disordered nano-sized aggregates. However, once supersaturation is generated, drug molecules 
have a tendency to crystallize in order to reduce their chemical potential. With crystallization 
inhibitors (the parachute), the generated supersaturation can be kinetically maintained and 
controlled in order to increase drug absorption.8 Polymeric additives, e.g., poly vinylpyrrolidone 
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(PVP) based polymers and cellulose derivatives, have been commonly used in commercial 
formulations to inhibit crystallization. Ilevbare et al.9, 10 exploited the anti-nucleation and growth 
inhibition properties of a group of chemically and structurally diverse polymers. The relative 
hydrophobicity and intermolecular interactions between drugs and polymers were suggested to be 
important factors impacting crystallization kinetics. Besides polymeric additives, there has been 
increasing use of surfactants in amorphous solid dispersion formulations. Surfactants are often 
added to improve the processing properties of formulations or used as solubilizing agents to 
improve the drug solubility.  Recently, the impact of surfactants on the crystallization kinetics of 
active pharmaceutical ingredients has attracted attention. It has been shown that surfactants can 
either enhance or inhibit nucleation11, 12 and crystal growth,13 and influence polymorphic 
transformations.14 Furthermore, an inconsistency between the concentration-based supersaturation 
ratio and solute thermodynamic activity, which is the fundamental driving force for crystallization, 
has been observed for some systems when solubilizing additives such as surfactants are present.4 
A fundamental understanding of the impact of surfactants on supersaturation and crystallization 
kinetics is critical for formulation design and performance assessment of poorly soluble drugs. 
 Chen et al.11 evaluated the impact of commonly used surfactants on the crystallization 
of celecoxib supersaturated solutions, and sodium taurocholate (STC), a member of the bile salt 
family, was found to inhibit crystallization. Bile salts, as biological surfactants, are the main 
product of cholesterol metabolism and form mixed micelles with lecithin and cholesterol in vivo. 
The biologically relevant bile salts found in human intestinal fluids are sodium taurocholate (STC), 
sodium taurodeoxycholate (STDC), sodium taurochenodeoxycholate (STCDC), sodium 
glycocholate (SGC), sodium glycodeoxycholate (SGDC), and sodium glycochenodeoxycholate 
(SGCDC) (Table 1).15 Despite the fact that at least six different kinds of bile salts exist in the GI 
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milieu, STC is the only bile salt present in commercial Fasted State Simulated Intestinal Fluid 
(FaSSIF) and Fed State Simulated Intestinal Fluid (FeSSIF).  The general structure of bile salts 
consists of a steroid ring system with hydroxyl groups distributed on one side, leading to facial 
polarity.  Because of their unique molecular structure, the pattern of bile salt aggregation is not 
analogous to typical aliphatic surfactants. Previous studies have shown that the aggregation of bile 
salts is complex and step-wise,16, 17 and the aggregation is found to occur over a relatively wide 
range of concentrations compared to other types of surfactants.18 The broad critical micelle 
concentration (CMC) range has led to difficulties in characterizing the aggregation behavior, and 
bile salts are thought to solubilize solutes by different mechanisms as compared to traditional 
surfactants. Changing the functional groups on the bile salt scaffold impacts the CMC,19 which in 
turn is expected to result in different solubilization abilities among different bile salts. The reported 
CMC values for biologically relevant bile salts are in the range of 2 to 12mM. 18, 20 In general, the 
effect of bile salts on supersaturated solutions containing poorly water soluble APIs has been 
studied to a limited extent. However, this is an important area of research given the increasing use 
of supersaturating dosage forms to improve the oral absorption of poorly water soluble compounds.  
 In order to better understand the impact of bile salts on supersaturated API solutions, 
two key questions were addressed in this study. First, how does a bile salt, at a concentration above 
and below the CMC, affect the thermodynamic properties of supersaturated solutions containing a 
model poorly water soluble API? Here, the interplay between solubilization and membrane 
transport is studied. Second, is sodium taurocholate a good surrogate for other bile salts in terms 
of impact on supersaturated solutions?  Most in vitro studies of bile salt solutions focus on those 
containing sodium taurocholate. However, several different bile salts have been identified from 
human aspirates of intestinal fluid, and some of these are present in higher concentration than STC. 
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Hence it is imperative to understand if bile salts are interchangeable with respect to their impact 
on the thermodynamics of supersaturated solutions. In this work, we systematically evaluated the 
impact of six biologically relevant bile salts on supersaturated telaprevir solutions. Telaprevir is a 
poorly soluble drug with high glass transition temperature and large reported supersaturation 
window.21 The thermodynamic properties of supersaturated telaprevir solutions, including the 
equilibrium solubility and the onset of glass-liquid phase separation, were determined in the 
absence and presence of four taurine/glycine conjugated dihydroxy (STDC, STCDC, SGDC and 
SGCDC) and trihydroxy (STC and SGC) bile salts. The impact of bile salts on supersaturated 
telaprevir solutions was evaluated in terms of their aggregation state and differences in molecular 
structure, respectively. 
 
MATERIALS  
 Telaprevir was obtained from Attix Pharmaceuticals (Toronto, Ontario, Canada) and 
ChemShuttle (CA). Hydroxypropyl methyl cellulose acetate succinate grade AS-MF (HPMCAS-
MF) was obtained from Shin Etsu Chemical Co., Ltd (Tokyo, Japan). Sodium taurocholate 
(practical grade, MP BiRPHGLFDOV//&2+ VRGLXPJO\FRFKRODWH &KHP-,PSH[ ,QW¶O
Inc., IL), sodium taurodeoxycholate ( &KHP-,PSH[ ,QW¶O ,QF ,/), sodium 
JO\FRGHR[\FKRODWH6LJPD02), sodium taurochenodeoxycholate (98%, Sinova Inc., MD) 
and sodium glycochenodeoxycholate (&KHP-,PSH[,QW¶O,QF,/) were used as received. 
Molecular structures of telaprevir and the six bile salts are shown in Figure 1 and Table 1. A 
regenerated cellulose membrane with a molecular weight cutoff (MWCO) of 6-8k Da was acquired 
from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). The aqueous media used in all 
experiments was 50mM pH 6.5 sodium phosphate buffer.  
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METHODS  
Crystalline Solubility Measurements.  
 The solubility of crystalline telaprevir in different media was determined by adding 
an excess amount of the drug to 15mL of 50 mM pH 6.5 phosphate buffer solution with or without 
bile salt. Bile salts were present in solution at a concentration of 1.86mM (monomer level) or a 
12mM (micellar level). The solutions were stirred at 300rpm and equilibrated for 48 h in a water 
bath at 37 °C. Samples were then ultracentrifuged in an Optima L-100 XP ultracentrifuge equipped 
with a Swinging-Bucket Rotor SW 41 Ti (Beckman Coulter, Inc., Brea, CA) at 35000 rpm for 30 
min at 37 °C. The supernatant obtained was diluted 2-fold with methanol, and the concentration 
of the supernatant was determined with a SI Photonics UV/vis spectrometer (Tuscon, Arizona), 
fiber optically coupled with a 2 cm path length dip probe at a wavelength of 270 nm. The standard 
curve presented good linearity (R2> 0.99) over the relevant concentration range. 
UV/Vis Extinction Measurements. 
 UV extinction measurements were used to determine the onset of glass-liquid phase 
separation (GLPS) in supersaturated telaprevir solutions. A syringe pump (Harvard Apparatus, 
Holliston, MA) was used to add the predissolved telaprevir methanol stock solution (12 mg/mL) 
at 0.05 mL/min to 15 mL of 50 mM pH 6.5 phosphate buffer, with or without dissolved bile salts, 
stirred at 300 rpm at 37 °C. Bile salts were present in solution at a concentration of 1.86 mM 
(monomer level) or 12 mM (micellar level). The formation of a drug-rich phase in solution, i.e., 
the onset of glass-liquid phase separation, leads to light scattering and can be detected from an 
increase in the UV signal at a non-absorbing wavelength (370nm in this study). The change in the 
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signal at 370 nm was monitored using the SI Photonics UV/vis spectrometer (Tuscon, Arizona), 
fiber-optically coupled with a 1 cm path length dip probe. 
Ultracentrifugation Method. 
 Pre-dissolved telaprevir methanol solution (12 mg/mL and 20 mg/mL) was added to 
15 mL of 50 mM pH 6.5 phosphate buffer, with or without dissolved bile salts, and stirred at 300 
rpm at 37 °C, to produce a solution with a concentration above the concentration where GLPS 
occurs. Bile salts were present in solution at a concentration of 1.86 mM or 12 mM. The resultant 
turbid solutions were then ultracentrifuged in an Optima L-100 XP ultracentrifuge equipped with 
a Swinging-Bucket Rotor SW 41 Ti (Beckman Coulter, Inc., Brea, CA) at 35000 rpm for 40 min 
at 37 °C. Once the supernatant was separated from the disperse drug-rich phase, the supernatant 
obtained was diluted 2-fold with methanol, and the concentration of telaprevir in the supernatant 
was measured using the SI Photonics UV/vis spectrometer (Tuscon, Arizona), fiber optically 
coupled with a 0.2 cm path length dip probe at a wavelength of 270 nm. The standard curve 
presented good linearity (R2> 0.99) over the relevant concentration range. 
Diffusion Rate Measurements. 
 A side-by-side diffusion cell (PermeGear, Inc. Hellertown, PA), as depicted in Figure 
2, was used to evaluate solute flux across membrane for solutions of telaprevir in the absence and 
presence of different bile salts at various solute concentrations. These measurements were then 
used to estimate the solute (telaprevir) thermodynamic activity in solutions containing bile salts. 
The 34 mL donor and receiver chambers were separated by a regenerated cellulose membrane with 
a molecular weight cut off (MWCORIí.'DDQGFRQQHFWHGZLWKDQRULILFHdiameter of 30 
mm. The membranes were hydrated in deionized water overnight before experiments. In each 
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experiment, both the donor and receiver chamber were filled with 32 mL of 50 mM pH 6.5 sodium 
phosphate buffer with 5 ȝJP/+30&$6-MF (to prevent crystallization). Control experiments in 
the absence of HPMCAS-MF were conducted.  The mass flow rate results are consistent, 
indicating that the polymer does not affect solution thermodynamics at the concentration used. For 
systems with bile salts, an equal concentration of bile salt was added in both receiver and donor 
chambers, hence there was no driving force for bile salt diffusion. A methanolic stock solution of 
telaprevir (12 or 20 mg/mL) was added to the donor chamber to obtain the desired concentration. 
The concentration change in the receiver chamber was monitored by a SI Photonics UV/vis 
spectrometer (Tuscon, Arizona), fiber optically coupled with a 2 cm path length dip probe, at a 
wavelength of 270 nm. The standard curve presented good linearity (R2> 0.99) over the relevant 
concentration range. The slope of the concentration versus time profile of the receiver chamber 
was obtained by linear regression, and used as the estimated mass flow rate. A typical example of 
changes in the UV signal as a function of time is shown in Figure S1, Supporting Information. The 
mass flow rate, F, of telaprevir molecules diffusing across the membrane, is a function of the 
diffusion coefficient D, the membrane cross-sectional area S, the solute thermodynamic activity ܽ, 
the thickness of the membrane h, and the activity coefficient of telaprevir in the membrane, Ȗm. 
The activity of telaprevir can be further expressed as a function of the activity coefficient of 
telaprevir, Ȗ, and the telaprevir concentration C in the donor chamber. 
 ܨ ൌ ݀݀ܯݐ ൌ ܦ݄ܵܽߛ௠  (1) 
 ܽ ൌ ܥߛ (2) 
In all experiments, the membrane cross-sectional area S, and the thickness of the membrane h are 
constant. The activity coefficient of telaprevir in the membrane Ȗm and diffusion coefficient D are 
also assumed to be constants as well. Sink conditions were assumed, i.e. the thermodynamic 
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activity of telaprevir in the receiver compartment was considered negligible. This assumption is 
reasonable as the maximum concentration obtained in the receiver chamber was always less than 
one-half of the crystalline solubility. Membrane permeability was assumed to be unchanged for 
the different systems, hence the change in solute mass flow is assumed to be due to the change in 
solute activity.  
 
RESULTS  
Crystalline Solubility and the Onset of GLPS 
 The equilibrium crystalline solubility values for telaprevir in the absence and presence 
of six different bile salts in 50 mM pH 6.5 phosphate buffer are summarized in Table 2. In the 
presence of monomer level bile salts (1.86 mM bile salt concentration, about 0.1 w/w %), no 
significant solubilization was observed. On the other hand, the crystalline solubility of telaprevir 
increased about 2-fold in the presence of a micellar level of all of the dihydroxy bile salts (STDC, 
STCDC, SGDC, and SGCDC) while no significant solubilization was observed in the presence of 
a micellar level of either trihydroxy bile salt (STC and SGC). Surfactants are commonly used in 
commercial formulations of poorly soluble APIs, whereby more than ten-fold solubility 
enhancement can be readily achieved locally due to drug incorporation into surfactant micelles.3, 
22  However, the bile salts investigated in this study are not strong solubilizers of telaprevir at the 
concentrations employed, even when these concentrations are above their CMC.  
 Telaprevir is a compound with high glass transition temperature, and has been shown 
to undergo GLPS in highly supersaturated solutions.21, 23 Figure 3 summarizes the telaprevir 
concentration where GLPS was observed in the absence and presence of six different bile salts. It 
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is apparent that the three approaches used to make these GLPS measurements, namely the UV 
extinction method, ultracentrifugation method and diffusion rate measurements give similar values 
for GLPS onset. The ultracentrifugation and diffusion rate approaches are likely to provide values 
close to the coexistence concentration of the continuous phase, while the UV extinction method, 
where the drug is added continually, might approach one of the spinodal decomposition points for 
phase separation.24 However, given the good agreement between the three methods, it is apparent 
that the system does not undergo substantial supersaturation with respect to GLPS in agreement 
with previous observations.25, 26  Figure 4 shows an example of the UV extinction experiment of 
telaprevir in 50mM pH 6.5 phosphate buffer, in which the onset of GLPS is indicated by increased 
light scattering due to the spontaneous formation of a drug-rich phase in the solution when the 
concentration exceeds a certain value. By subsequently separating the drug-rich dispersed phase 
from the continuous phase, using ultracentrifugation to pellet the drug-rich phase, the composition 
of the continuous phase can be determined, thereby yielding one of the binodal points (at 37°C).24  
Diffusion rate measurements were also implemented to determine the concentration of telaprevir 
in the continuous phase following GLPS. Figure 5a shows the concentration in the receiver 
chamber as a function of time, from which telaprevir mass flow rate for different donor chamber 
concentration levels (shown in Figure 5b) can be determined from the slope. The linearity of each 
concentration versus time plot in Figure 5a confirms the constant parameter assumption (the 
membrane cross-sectional area S, the thickness of the membrane h, the activity coefficient of 
telaprevir in the membrane Ȗm and the diffusion coefficient D) in equation (1). As shown in Figure 
5b, telaprevir mass flow rate across the cellulose membrane increases linearly as a function of 
donor chamber concentration. At donor concentrations DERYHȝJP/, the mass flow rate of 
telaprevir reaches a plateau. At these concentrations, solutions in the donor chamber were observed 
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to be turbid, indicating that phase separation had occurred. It has been shown in previous studies 
that the maximum mass flow rate of poorly soluble APIs is obtained with supersaturated solution 
at or above concentrations where LLPS/GLPS occurs.[3]  Therefore, flux measurements can be 
used to determine the onset of LLPS/GLPS from the concentration where the maximum in mass 
flow rate is observed. Based on all of the implemented methods, the GLPS onset of telaprevir in 
50 mM pH 6.5 phosphate buffer is about ȝJP/. This value is about 1.5 fold higher than the 
value reported in 100 mM pH 6.8 phosphate buffer.21 Hence the effect of buffer ionic strength and 
pH on telaprevir GLPS onset concentration was investigated. Figure 6 summarizes the GLPS 
concentration of telaprevir in different media, determined using the UV/Vis extinction and 
centrifugation method. The GLPS concentration decreases with increased buffer salt concentration. 
This is due to the promoted aggregation of molecules via hydrophobic interactions in a medium of 
increased ionic strength, and similar pattern of behavior has been observed for supersaturated 
ritonavir solutions7, as well as for other aggregation-based phenomena such as micelle formation27.  
 The impact of bile salts on the concentration where telaprevir undergoes GLPS reveals 
some interesting patterns with regard to bile salt molecular structure (Figure 3). For trihydroxy 
bile salts (STC and SGC), the presence of both monomer and micellar level bile salts slightly 
increases the GLPS onset concentration; however, the aggregation state of bile salts does not 
appear to significantly affect the onset concentration of GLPS. For the dihydroxy bile salts, 
micellar levels of STDC and SGDC increased the GLPS onset concentration of telaprevir by a 
factor of 2. Thus, micellar level dihydroxy bile salts have a stronger interaction with telaprevir 
molecules, consistent with the crystalline solubility data. For solutions containing STCDC and 
SGCDC, the onset of GLPS was difficult to determine using the UV extinction method. Taking 
solutions containing SGCDC as an example, an immediate increase of light scattering (extinction) 
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upon the addition of pre-dissolved telaprevir methanol stock solution was seen. There was no 
visual change in solution turbidity until much higher concentrations were reached. Solutions were 
evaluated using an optical microscope with cross-polarized light, and no crystals/aggregates could 
be observed suggesting that the scattering species are of a size below the detection limit. We 
suspect complex formation between drug and bile salt, with some supporting evidence provided 
by the diffusion data. Therefore, only the ultracentrifugation and/or flux methods are reported for 
these systems. Solutions with STCDC or SGCDC at concentrations above the onset concentration 
determined by flux methods were observed to be visually turbid. For monomeric STCDC, the onset 
concentration of GLPS was slightly lower than for pure telaprevir, while the value was 
approximately doubled in the presence of micellar STCDC. SGCDC resulted in a small increase 
in the GLPS concentration in both monomeric and micellar form.    
Impact of Bile Salts on Telaprevir Diffusion Rates 
  Mass flow rate of telaprevir solutions of different concentrations in the presence of 
bile salts were studied using a diffusion cell. The impact of bile salts on the mass flow rate can be 
again divided into three categories based on bile salt molecular structures.  As shown in Figure 7a, 
the presence of either monomeric or micellar levels of trihydroxy bile salt (STC and SGC) did not 
have a major impact on the diffusion mass flow rate of a telaprevir solution of a given 
concentration. The impact of STC on the diffusion mass flow rate at an even higher bile salt 
concentration (18mM) was also tested (data not shown), and no significant change in mass flow 
rate was again observed. Maximum mass flow rates were achieved at concentrations at or above 
the GLPS concentration of telaprevir in the presence of the relevant bile salts. For STDC and 
SGDC, dihydroxy bile salt with the absence of hydroxyl group at R3 position on the steroid ring 
system, no effect on mass flow rate was observed in the presence of monomeric bile salt (Figure 
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7b). On the other hand, a ~2-fold reduction in mass flow rate for a given telaprevir concentration 
was observed in the presence of micellar level bile salts. From equation 1, the decrease in mass 
flow rate indicates a decrease in telaprevir activity in the presence of micellar bile salt. A similar 
trend has been observed in a previous study with felodipine, a poorly soluble API, in the presence 
of Vitamin E TPGS (surfactant).  At Vitamin E TPGS concentrations below the CMC, the mass 
flow rate of felodipine remained unchanged compared to the solution without Vitamin E TPGS. 
However, a major decrease in felodipine mass flow rate was observed with a concurrent enhanced 
equilibrium crystalline solubility at Vitamin E TPGS concentrations above CMC. 4 From both the 
equilibrium crystalline solubility and mass flow rate data, it is apparent that STDC and SGDC 
solubilize telaprevir by incorporation of the drug into bile salt micelles. For STCDC, a dihydroxy 
bile salt lacking a hydroxyl group at R4 position on the steroid ring system, a similar trend is 
observed as for the aforementioned dihydroxy bile salts (Figure 7c). In contrast, the final 
dihydroxy bile salt studied (SGDC) showed a different pattern of behavior. For this system, mass 
flow rate was observed to decrease in the presence SGCDC, but no difference was observed 
between bile salt concentrations above and below CMC. Interestingly, the maximum observed 
mass flow rate decreases in the presence of both STCDC and SGCDC, indicating that the 
maximum achievable supersaturation decreases. The decreases in maximum achievable mass flow 
rate are statistically significant (t test, p value<<0.05).  The maximum achievable mass flow rate 
is reduced by the presence of STCDC and SGCDC to about three fourths of the value in the absence 
of bile salt. 
 Raina et al. 4 mentioned a possible scenario where the maximum supersaturation of solute 
decreases in the presence of additives. Trasi et al.28 and Alhalaweh et al. 29 have shown that the 
maximum achievable supersaturation of a poorly water-soluble compound can be reduced by the 
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presence of a second solute, if the two solutes are miscible in the liquid phase. In our case, the 
reduced maximum mass flow rate in the presence of STCDC and SGCDC suggests mixing of these 
two bile salts with the telaprevir drug-rich phase. 
 
DISCUSSION 
 Solution thermodynamics play a critical role in the oral drug delivery of poorly water 
soluble drugs, especially for supersaturation strategies such as using amorphous solid dispersions. 
The extent of supersaturation is important since it influences membrane transport rate,5, 30 as well 
as providing the driving force for crystallization. Hence, a better understanding of how components 
present in the solution impact drug solution thermodynamics is necessary, both to select 
appropriate additives that enhance the apparent solubility of the drug without affecting the apparent 
permeability, and to deconvolute mechanisms of solubility enhancement, namely solubilization 
versus supersaturation. In addition, the presence of various solubilizing components, such as bile 
salts, in human intestinal fluids further complicates the in vivo dissolution of drugs. In order to 
improve prediction of in vivo behavior, it is crucial to gain insights into solution thermodynamics 
of biologically relevant media. 
 Diffusion rate measurements across a membrane serve as a method to evaluate the 
thermodynamic activity of a solute in the presence of additives. This in turn enables determination 
of the level of supersaturation. Determining supersaturation is essential for understanding if 
additives alter crystallization kinetics by changing the supersaturation of the system, or via other 
effects.  Fundamentally, supersaturation can be expressed in terms of the chemical potential 
difference between the solute in the solution of interest and in its equilibrium state:31 
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  ߜ ൌ ߤ െ ߤ ?ܴܶ ൌ  ܽܽ ? (3) 
where ߤ is the chemical potential of the solute, ܴ is the ideal gas constant, ܶ is temperature, and ܽ 
is the solute activity.  ? indicates the property at standard state (solute in a solution in equilibrium 
with crystalline state in this study). The maximum achievable supersaturation is limited by the 
amorphous solubility of the solute, above which liquid-liquid (or glass-liquid) phase separation 
occurs. Thus in the absence of crystallization, addition of further solute above this concentration 
leads to the formation of an amorphous solute-rich disperse phase.24 Therefore, we can define the 
maximum achievable supersaturation ratio as: 
  ߜெ௔௫ ൌ  ܽ௔௠௢௥௣௛௢௨௦ܽ௖௥௬௦௧௔௟௟௜௡௘  (4) 
For a simple dilute system, it is reasonable to assume that the solute activity coefficient remains 
constant over the concentration range encompassing the crystalline and amorphous solubilities. 
Hence, combining equations 2 and 4, the maximum achievable supersaturation following 
LLPS/GLPS can be expressed in terms of amorphous to crystalline solubility ratio: 
  ߜெ௔௫ ൌ  ܥ௔௠௢௥௣௛௢௨௦ܥ௖௥௬௦௧௔௟௟௜௡௘  (5) 
However, in systems with additives or bile salts that interact with the solute of interest, the solute 
activity coefficient changes. The level of discrepancy between concentration-based 
supersaturation and activity-based supersaturation varies, depending on intermolecular 
interactions between solute, solvent and additives and how these vary as a function of 
supersaturation. In such instances, it may no longer be accurate to use concentration ratios to 
determine the supersaturation in the system. This concept has been discussed previously in the 
context of surfactant systems.4  
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 Figure 8 summarizes the impact of the six bile salts on telaprevir mass flow rates. In 
our diffusion rate experiment setup, the solute mass flow rate is assumed to be directly proportional 
to solute activity (see equation 1). The ratio of solute mass flow rate in the solution of interest to 
the mass flow rate of its standard state (solute in a solution in equilibrium with crystalline state in 
this study) thus yields the fundamental supersaturation:  
 
ܨܨ ? ൌ ܦܵ௠݄ߛ௠ ܽܦܵ௠݄ߛ௠ ܽ ? ൌ ܽܽ ? ൌ ߜ (6) 
It should be noted that F° should be constant for systems in the absence and presence of bile salts 
if our assumptions are reasonable (i.e. D, Sm, h and Ȗm are constants). This was confirmed by 
extrapolating the telaprevir mass flow rate versus concentration data to a concentration 
corresponding to the crystalline solubility (values taken from Table 2) for systems in the absence 
and presence of bile salts.  F° values are comparable within experimental error confirming that our 
assumptions appear reasonable.  
Figure 9 shows the relationship between the fundamental supersaturation į and the commonly used 
concentration-based supersaturation for telaprevir (below the GLPS concentration) in the absence 
of any bile salts. The curve has a slope very close to 1, indicating that the activity coefficient ratio 
is 1 and hence the activity coefficient of telaprevir in buffer is constant over the concentration 
range studied.  Thus this system can be used as a calibration curve, using the measured mass flow 
rate value of a telaprevir solution where the solute activity coefficient is unknown (i.e. a solution 
containing bile salts), to determine the corresponding fundamental supersaturation. Knowing the 
extent of activity-based supersaturation is essential to evaluate crystallization kinetics in media 
containing bile salts, enabling experiments to be conducted at a comparable thermodynamic 
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driving force. In the literature, concentration-based supersaturations have long been employed in 
crystallization studies. 32, 33 However, from equations (2) and (3), the fundamental supersaturation 
and the concentration-based supersaturation are only equivalent when the solute activity 
coefficient ratio is unity in systems of interest. Figure 10 clearly shows the discrepancy between 
the fundamental supersaturation (a/ao) and the concentration-based supersaturation (C/Co) for 
telaprevir supersaturated solutions. The deviation between concentration-based supersaturation 
and activity-based supersaturation varies both with bile salt type as well as their aggregation state. 
Taking į = 5.0 as an example, the corresponding concentration-based supersaturation varies 
between 3.9 ~ 6.7 for the different additive systems. It is well know from theoretical considerations 
as well as experimental observations that crystallization kinetics, in particular nucleation rates, are 
highly dependent on the supersaturation level.33 Thus the measurements presented herein provide 
an improved approach for the estimation of crystallization driving forces in solutions containing 
bile salts and other solubilizing additives, which in turn will enable better understanding of how 
additives modify crystallization kinetics.  
 Based on equations 1 and 2, the deviation of the slope of each curve (before the plateau 
region) from the slope of the calibration curve in Figure 8 represents the change in the activity 
coefficient of telaprevir in the presence of the corresponding bile salt.  
 
݀ܨ݀ܥሺ݀ܨ݀ܥሻௗ௥௨௚௜௡௕௨௙௙௘௥ ൌ ߛߛௗ௥௨௚௜௡௕௨௙௙௘௥ (7) 
 
Thus the variation of slopes between the curves for telaprevir in the presence of bile salts and the 
curve for telaprevir in the absence of any bile salts reveals the six bile salts in their monomeric and 
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micellar form uniquely impact solution thermodynamics. Bile salts are known to exhibit stepwise 
aggregation in solution, and the reported CMC values for the bile salts used in this study are 
between the range of 2-12mM.18, 20 Therefore, assuming that telaprevir does not alter the CMC, at 
a bile salt concentration of 1.86mM, the solution will contain the monomeric form, while at 12mM, 
a mixture of micelles and monomers will be present. From Figure 8, it is evident that monomeric 
bile salts have minimal interaction with telaprevir, with the exception of SGCDC. This is apparent 
from the unaltered flux versus concentration profile for these systems. However, at concentrations 
where micelles are present, the slopes of the flux versus concentration plots are reduced, indicating 
that the activity-based supersaturation at a given telaprevir concentration is reduced. The 
dihydroxy bile salts have stronger interaction with telaprevir molecules than trihydroxy bile salts, 
reducing the supersaturation to a greater extent at a given telaprevir concentration, which also 
approximately correlates with the extent of solubilization of the crystalline form observed in this 
study (Table. 2). One possible explanation for the greater extent of interaction of the dihydroxy 
bile salts is the hydrophobicity of bile salts molecules. Trihydroxy bile salts are less hydrophobic 
and have higher CMCs than dihydroxy bile salts,34 and hence there will be a lower extent of 
micellization for trihydroxy bile salts at a concentration of 12mM relative to for the dihydroxy bile 
salts. Hydrophobic drug molecules can be incorporated into bile salt aggregates.35 Based on the 
Stokes±Einstein equation,36 the diffusion coefficient of a particle is inversely proportional to its 
radius. That is, diffusion rate of a particle decreases with increasing particle size. The decrease in 
telaprevir mass flow rate in solutions containing dihydroxy bile salt micelles suggests that 
telaprevir molecules are incorporated into bile salt aggregates, forming larger particles in the 
solution. For trihydroxy bile salts, no comparable decrease in mass flow rate was observed even 
at concentrations higher than the reported CMCs (data not shown). This is consistent with a 
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previous solubilization study of bile salts,37 where dihydroxy bile salts showed a greater extent of 
solubilization of various drugs as compared to trihydroxy bile salts. On the other hand, no impact 
of a different conjugation group at R5 position on the steroid ring system is observed.   
 Using the activity calibration, in combination with the amorphous and crystalline 
solubility values, phase boundaries in the presence of bile salts are summarized in schematic form 
in Figure 11. In systems with the trihydroxy bile salts (STC and SGC), crystalline solubility and 
the onset concentration of GLPS are only marginally changed compared to the control (telaprevir 
only), thus these bile salts have minimal impact on either the concentration- or activity-based 
boundaries (Figure 11a). Figure 11b shows that micellar STDC and SGDC dihydroxy bile salts 
significantly increase the crystalline solubility and the onset concentration of GLPS, but the 
thermodynamic activity-based boundaries remained unchanged. In other words, the bile salts do 
not change the thermodynamic activity of either the crystalline or amorphous phases for the 
systems shown in Figures 11a-b, indicating that the composition of these phases are not altered in 
the presence of the bile salts. However, since STDC and SGDC do alter the crystalline and 
amorphous solubility values, the slopes of the flux versus telaprevir concentration profiles are 
altered, due to solubilization of the drug. Hence there is a difference between the activity and 
concentration-based regions of the schematic in terms of supersaturation. In Figure 11c, it is clear 
that not only did solubilization of telaprevir occur in the presence of micellar STCDC, but that the 
thermodynamic supersaturation window became narrower for both monomeric and micellar 
STCDC. This presumably stems from the mixing of STCDC into the telaprevir drug-rich phase 
upon GLPS, leading to a reduced activity of telaprevir in the drug-rich phase.28, 29, 38, 39 For SGCDC 
(Figure 11d), the maximum achievable supersaturation also decreases in the presence of both 
monomeric and micellar bile salts, indicating mixing of SGCDC and the telaprevir drug-rich phase.  
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 Thus, for the telaprevir solution system, we observed at least three types of impact on 
solution thermodynamics amongst the six biologically relevant bile salts. It is obvious that STC, 
the only bile salt component in commercial simulated fluids, is not an adequate surrogate for the 
entire bile salt family. As noted in the literature, SGC, STCDC and SGCDC are more abundant in 
vivo than STC,15 hence in vitro testing with current simplified STC based FaSSIF simulated medias 
could potentially lead to inaccurate prediction of drug in vivo supersaturation and crystallization 
rates.  
 
CONCLUSION 
 To maximize oral absorption of poorly soluble drugs, it is crucial to understand how 
endogenous bile salts impact drug solution thermodynamics. In this study, we have demonstrated 
that bile salts alter the thermodynamics of supersaturated telaprevir solutions. A new approach is 
proposed for better estimation of crystallization driving forces in solutions containing bile salts 
and other solubilizing additives. Furthermore, bile salts representative of the most prevalent 
species found in human intestinal fluids, show different patterns of interaction with supersaturated 
telaprevir solutions and hence are not interchangeable. Overall, trihydroxy bile salts have less 
effect on telaprevir solution thermodynamics than dihydroxy bile salts. These observations lay the 
framework for mechanistic studies into the impact of bile salts on crystallization kinetics as a 
function of the fundamental supersaturation.  
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TABLES  
Table 1. Chemical structure of bile salts. 
 
Bile salt Abbreviation R1 R3 R4 R5 
Sodium taurocholate STC OH OH OH NHCH2CH2SO3
- 
Sodium taurodeoxycholate STDC OH H OH NHCH2CH2SO3
- 
Sodium taurochenodeoxycholate STCDC OH OH H NHCH2CH2SO3
- 
Sodium glycocholate SGC OH OH OH NHCH2COO
- 
Sodium glycodeoxycholate SGDC OH H OH NHCH2COO
- 
Sodium glycochenodeoxycholate SGCDC OH OH H NHCH2COO
- 
 
 
 
 
R1 R3 
R4 
R5 
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Table 2. Impact of bile salts on equilibrium crystalline solubility of telaprevir at 37 °C. 
 Crystalline solubility of Telaprevir (µg/mL) 
Bile salt 
concentration 
STC STDC STCDC SGC SGDC SGCDC 
12 mM 6.7±1.2 11.1±0.6 12.2±0.6 6.2±0.4 12.4±1.3 9.6±0.6 
1.86 mM 6.0±0.9 5.6±0.3 6.8±0.7 5.5±0.4 6.9±0.8 5.7±0.8 
0 mM 5.2±0.1 
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FIGURES  
 
Figure 1. Molecular structure of telaprevir.  
 
 
Figure 2. Side-by-side diffusion cell apparatus used for mass flow rate experiments. 
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Figure 3. Onset concentration of GLPS in the presence of bile salts, n= 3 and error bars 
represent standard deviation.  
 
 
 
Figure 4. Determination of GLPS concentration of telaprevir with UV extinction method.  
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Figure 5. Diffusion cell results (a) concentration versus time profile for telaprevir in the receiver 
chamber, and (b) diffusion mass flow rate versus telaprevir concentration in buffer. 
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Figure 6. The effect of buffer ionic strength and pH on telaprevir GLPS onset concentration. 
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Figure 7c. Diffusion mass flow rate versus telaprevir concentration in the presence of (a) STC 
and SGC, (b) STDC and SGDC, and (c) STCDC and SGCDC. 
 
 
Figure 8. Diffusion mass flow rate versus telaprevir concentration in the presence of bile salts. 
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Figure 9. The relationship between concentration-based supersaturation and the fundamental 
supersaturation for telaprevir in the absence of bile salts. 
 
Figure 10. The relationship between concentration-based supersaturation and the fundamental 
supersaturation for telaprevir in the absence and presence of bile salts. The dotted line represents 
the theoretical curve with a slope of 1.  
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Figure 11d. Visual depiction of the impact of (a) trihydroxy bile salt, (b) dihydroxy bile salt 
STDC and SGDC, (c) dihydroxy bile salt STCDC, and (d) dihydroxy bile salt SGCDC on phase 
boundaries and solute thermodynamic activity for supersaturated solutions of telaprevir.  
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